Related Experiment Video
Updated: May 10, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Growth hormone and cancer: an update on progress
Jo K Perry1, Dong-Xu Liu, Zheng-Sheng Wu
1Liggins Institute, University of Auckland, Auckland, New Zealand. j.perry@auckland.ac.nz
Current Opinion in Endocrinology, Diabetes, and Obesity
|June 29, 2013
Summary
Growth hormone receptor (GHR) deficiency may protect against cancer. Studies suggest the GH/IGF-1 axis promotes cancer, but GHR antagonism
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Growth hormone (GH) and its receptor (GHR) are implicated in cancer development.
- Deficiency in GHR is linked to reduced cancer risk in animal models.
- Elevated GH and GHR levels are observed in various human cancers.
Purpose of the Study:
- To review recent literature on the role of the GH/GHR axis in cancer.
- To explore the protective effects of GHR deficiency against cancer.
- To discuss the implications of GH/GHR in cancer progression and therapeutic resistance.
Main Methods:
- Literature review of studies on GH, GHR, and cancer.
- Analysis of animal models with GHR deficiency.
- Examination of human studies, including Laron syndrome patients.
- Investigation of GH signaling pathways and microRNA involvement.
Main Results:
- Congenital GHR deficiency appears to confer protection against cancer in humans and animals.
- GH expression in malignancies correlates with clinicopathological features and therapeutic resistance.
- Novel insights into GH signal transduction, including receptor crosstalk and microRNA regulation, have been identified.
Conclusions:
- The GH/insulin-like growth factor-1 axis plays a significant role in initiating and promoting cancer progression.
- Further clinical and translational studies are crucial to determine the therapeutic potential of GH or GHR antagonism in cancer treatment.
- Understanding the clinical association of GH expression in human malignancies is critical for future research.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.